Clinical Trial

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Study acronym: PENINSULA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-12; most recent amendment 2026-06-09.
Status change: Recruiting → Active, Not Recruiting 2026-06-09
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06318286
Lead Sponsor Hyogo Medical University
Collaborators: Merck Sharp & Dohme LLC
Conditions Malignant Pleural Mesothelioma
Enrollment 25 participants
Start Date 2024-03-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-10